speb/financial-data huggingface dataset:
NURECA.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 81080000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 12310000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 221780000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 5320000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 4180000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.34
NURECA.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 352690000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
NURECA.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 116470000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 396420000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 9549872.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 3.91
NURECA.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 252450000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 5000000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 5000000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 9549872.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 3.91
NURECA.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 37340000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — EBIT: 49400000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — EBITDA: 54400000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 143970000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 2760000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 2760000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Net Income: 37340000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 37340000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 37340000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Net Income Discontinuous Operations: 0.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 37340000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 37340000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 37340000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -2760000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -2760000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 54400000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 37340000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Operating Income: 27500000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 396420000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 21900000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 68300000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 46640000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 252450000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 5000000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 9300000.00
NURECA.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.20
NURECA.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 368920000.00
NURECA.NS income_statement (annual, 2026-03-31) — +Operating Expense: 465660000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 118550000.00
NURECA.NS income_statement (annual, 2026-03-31) — +Total Revenue: 1469630000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 354050000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 50820000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 50820000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 77490000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 77490000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Accumulated Depreciation: -38940000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -38940000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Additional Paid In Capital: 840270000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 840270000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -3000000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -3000000.00
NURECA.NS income_statement (annual, 2026-03-31) — Amortization: 2830000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Amortization Cash Flow: 2830000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 636170000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 636170000.00
NURECA.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 9863326.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 9444961.00
NURECA.NS income_statement (annual, 2026-03-31) — Basic EPS: 2.11
NURECA.NS income_statement (quarterly, 2026-03-31) — Basic EPS: -6.45
NURECA.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 32410000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Buildings And Improvements: 20000000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 20000000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -68290000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 15430000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 15430000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 95420000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 95420000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 14610000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 14610000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 130230000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 130230000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Cash Equivalents: 0.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Cash Equivalents: 0.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Cash Financial: 14610000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Cash Financial: 14610000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -75880000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: 28220000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: 34990000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Change In Payable: -14910000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -44270000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -71850000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Changes In Cash: -17720000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Common Stock: 95420000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 95420000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 1807590000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 1807590000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Common Stock Payments: -156680000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 5780000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 5780000.00
NURECA.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 935450000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 214410000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Current Assets: 1146760000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 1146760000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 9320000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 9320000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Current Debt: 4960000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 4960000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 14280000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 14280000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Current Deferred Taxes Liabilities: 5700000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Current Deferred Taxes Liabilities: 5700000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 137770000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 137770000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 5610000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 5610000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Depreciation: 17340000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 20170000.00
NURECA.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 20170000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 4480000.00
NURECA.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 17340000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 4480000.00
NURECA.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 9863326.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 9444961.00
NURECA.NS income_statement (annual, 2026-03-31) — Diluted EPS: 2.11
NURECA.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: -6.45
NURECA.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 20820000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -60920000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Dividends Payable: 120000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Dividends Payable: 120000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Dividends Received Cfi: 230000.00
NURECA.NS income_statement (annual, 2026-03-31) — EBIT: 54880000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — EBIT: -52110000.00
NURECA.NS income_statement (annual, 2026-03-31) — EBITDA: 75050000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — EBITDA: -47630000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Effect Of Exchange Rate Changes: -70000.00
NURECA.NS cash_flow (annual, 2026-03-31) — End Cash Position: 14610000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -195630000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Finished Goods: 445380000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Finished Goods: 445380000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: -35320000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: 81250000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: 410000.00
NURECA.NS income_statement (annual, 2026-03-31) — General And Administrative Expense: 19690000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 17010000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 17010000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Gross Accounts Receivable: 80490000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 80490000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 163600000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 163600000.00
NURECA.NS income_statement (annual, 2026-03-31) — Gross Profit: 534180000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 139640000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Hedging Assets Current: 2050000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Hedging Assets Current: 2050000.00
NURECA.NS income_statement (annual, 2026-03-31) — Interest Expense: 5100000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 3000000.00
NURECA.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 5100000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 3000000.00
NURECA.NS income_statement (annual, 2026-03-31) — Interest Income: 63610000.00
NURECA.NS income_statement (annual, 2026-03-31) — Interest Income Non Operating: 63610000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -21480000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 63510000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Inventory: 475060000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 475060000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 1814750000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 1814750000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: 144940000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 636170000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 636170000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Issuance Of Debt: 0.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Land And Improvements: 66650000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Land And Improvements: 66650000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 6110000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 6110000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 2200000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 2200000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 8310000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 8310000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Long Term Debt Issuance: 0.00
NURECA.NS cash_flow (annual, 2026-03-31) — Long Term Debt Payments: -8270000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 7880000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 7880000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Machinery Furniture Equipment: 71170000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 71170000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: -156680000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -700000.00
NURECA.NS income_statement (annual, 2026-03-31) — Net Income: 20820000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Net Income: -60920000.00
NURECA.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 20820000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -60920000.00
NURECA.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 20800000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -60920000.00
NURECA.NS income_statement (annual, 2026-03-31) — Net Income Discontinuous Operations: 20000.00
NURECA.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 20820000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -60920000.00
NURECA.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 20800000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -60920000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 49820000.00
NURECA.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 20820000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -60920000.00
NURECA.NS income_statement (annual, 2026-03-31) — Net Interest Income: 50770000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -3000000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: 145310000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: -15610000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: -8270000.00
NURECA.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: 50770000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -3000000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Net Other Investing Changes: 10000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Net PPE: 124660000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 124660000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -64120000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Net Short Term Debt Issuance: -7340000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 1790580000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 1790580000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 25410000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 25410000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 7880000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 7880000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Non Current Prepaid Assets: 6580000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 6580000.00
NURECA.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 159540000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 35740000.00
NURECA.NS income_statement (annual, 2026-03-31) — Normalized Income: 71494000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Normalized Income: -10898000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 32970000.00
NURECA.NS income_statement (annual, 2026-03-31) — Operating Income: 68520000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Operating Income: 21090000.00
NURECA.NS income_statement (annual, 2026-03-31) — Operating Revenue: 1469630000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 354050000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 9541920.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 9541920.00
NURECA.NS cash_flow (annual, 2026-03-31) — Other Cash Adjustment Outside Changein Cash: -10000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 157040000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 157040000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 34030000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 34030000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 1712180000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 1712180000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 17010000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 17010000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: -50040000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: -130000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: -130000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: 20000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 20000.00
NURECA.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 5330000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 10170000.00
NURECA.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 122540000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 73040000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Other Payable: 12470000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Other Payable: 12470000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Other Properties: 118770000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 118770000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 10790000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 10790000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 115620000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 115620000.00
NURECA.NS income_statement (annual, 2026-03-31) — Other Special Charges: 400000.00
NURECA.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Payables: 63410000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Payables: 63410000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 5610000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 5610000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Prepaid Assets: 157060000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 157060000.00
NURECA.NS income_statement (annual, 2026-03-31) — Pretax Income: 49780000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Pretax Income: -55110000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Properties: 0.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
NURECA.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: 140000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -976940000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -68290000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Raw Materials: 29680000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Raw Materials: 29680000.00
NURECA.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 935450000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 214410000.00
NURECA.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 20170000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 4480000.00
NURECA.NS income_statement (annual, 2026-03-31) — Rent And Landing Fees: 13100000.00
NURECA.NS income_statement (annual, 2026-03-31) — Rent Expense Supplemental: 13100000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: -15610000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Repurchase Of Capital Stock: -156680000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Restricted Cash: 294080000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 294080000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Retained Earnings: 885120000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 885120000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 1122250000.00
NURECA.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 4170000.00
NURECA.NS income_statement (annual, 2026-03-31) — Selling And Marketing Expense: 119800000.00
NURECA.NS income_statement (annual, 2026-03-31) — Selling General And Administration: 139490000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Share Issued: 9541920.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 9541920.00
NURECA.NS cash_flow (annual, 2026-03-31) — Short Term Debt Payments: -7340000.00
NURECA.NS income_statement (annual, 2026-03-31) — Special Income Charges: -3500000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 1807590000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 1807590000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 1790580000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 1790580000.00
NURECA.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: -33796000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -33348000.00
NURECA.NS income_statement (annual, 2026-03-31) — Tax Provision: 28980000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 5810000.00
NURECA.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.40
NURECA.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
NURECA.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: 790000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Total Assets: 1961570000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 1961570000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 1809790000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 1809790000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Total Debt: 22590000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 22590000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 1807590000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 1807590000.00
NURECA.NS income_statement (annual, 2026-03-31) — Total Expenses: 1401110000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 332960000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 153980000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 153980000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 814810000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 814810000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 16210000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 16210000.00
NURECA.NS income_statement (annual, 2026-03-31) — Total Other Finance Cost: 7740000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 5700000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 5700000.00
NURECA.NS income_statement (annual, 2026-03-31) — Total Unusual Items: -84490000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: -83370000.00
NURECA.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: -84490000.00
NURECA.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -83370000.00
NURECA.NS balance_sheet (annual, 2026-03-31) — Working Capital: 1008990000.00
NURECA.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 1008990000.00
NURECA.NS income_statement (annual, 2026-03-31) — Write Off: 3100000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — +Operating Expense: 127690000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — +Total Revenue: 403430000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Basic Average Shares: 9554517.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Basic EPS: 3.21
NURECA.NS income_statement (quarterly, 2026-06-30) — Cost Of Revenue: 246900000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Depreciation And Amortization In Income Statement: 6080000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Depreciation Income Statement: 6080000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Diluted Average Shares: 9554517.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Diluted EPS: 3.21
NURECA.NS income_statement (quarterly, 2026-06-30) — Diluted NI Availto Com Stockholders: 30670000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — EBIT: 46340000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — EBITDA: 52420000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Gross Profit: 156530000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Interest Expense: 2010000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Interest Expense Non Operating: 2010000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Net Income: 30670000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Net Income Common Stockholders: 30670000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Net Income Continuous Operations: 30680000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Net Income Discontinuous Operations: 0.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Net Income From Continuing And Discontinued Operation: 30670000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Net Income From Continuing Operation Net Minority Interest: 30670000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Net Income Including Noncontrolling Interests: 30680000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Net Interest Income: -2010000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Net Non Operating Interest Income Expense: -2010000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Normalized EBITDA: 53120000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Normalized Income: 31154457.48
NURECA.NS income_statement (quarterly, 2026-06-30) — Operating Income: 28840000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Operating Revenue: 403430000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Other Non Operating Income Expenses: 18200000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Other Operating Expenses: 77320000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Otherunder Preferred Stock Dividend: 0.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Pretax Income: 44330000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Reconciled Cost Of Revenue: 246900000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Reconciled Depreciation: 6080000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Tax Effect Of Unusual Items: -215542.52
NURECA.NS income_statement (quarterly, 2026-06-30) — Tax Provision: 13650000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Tax Rate For Calcs: 0.31
NURECA.NS income_statement (quarterly, 2026-06-30) — Total Expenses: 374590000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Total Unusual Items: -700000.00
NURECA.NS income_statement (quarterly, 2026-06-30) — Total Unusual Items Excluding Goodwill: -700000.00
NURS.V balance_sheet (annual, 2021-12-31) — Accumulated Depreciation: 0.00
NURS.V balance_sheet (annual, 2021-12-31) — Capital Lease Obligations: 0.00
NURS.V balance_sheet (annual, 2021-12-31) — Current Capital Lease Obligation: 0.00
NURS.V balance_sheet (annual, 2021-12-31) — Dueto Related Parties Current: 506200.00
NURS.V balance_sheet (annual, 2021-12-31) — Inventory: 0.00
NURS.V balance_sheet (annual, 2021-12-31) — Leases: 0.00
NURS.V cash_flow (annual, 2021-12-31) — Long Term Debt Payments: 0.00
NURS.V cash_flow (annual, 2021-12-31) — Net Short Term Debt Issuance: 0.00
NURS.V balance_sheet (annual, 2021-12-31) — Properties: 0.00
NURS.V cash_flow (annual, 2021-12-31) — Repayment Of Debt: 0.00
NURS.V income_statement (annual, 2021-12-31) — Research And Development: 150617.00
NURS.V income_statement (annual, 2021-12-31) — Restructuring And Mergern Acquisition: 0.00
NURS.V income_statement (annual, 2021-12-31) — Tax Provision: 10898.00
NURS.V balance_sheet (annual, 2021-12-31) — Total Debt: 0.00
NURS.V income_statement (annual, 2022-12-31) — +Operating Expense: 3794905.00
NURS.V income_statement (annual, 2022-12-31) — +Total Revenue: 4268431.00
NURS.V balance_sheet (annual, 2022-12-31) — Accounts Payable: 747492.00
NURS.V balance_sheet (annual, 2022-12-31) — Accounts Receivable: 5056.00
NURS.V balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -19912.00
NURS.V cash_flow (annual, 2022-12-31) — Asset Impairment Charge: 169269.00
NURS.V income_statement (annual, 2022-12-31) — Basic Average Shares: 3526305.00
NURS.V income_statement (annual, 2022-12-31) — Basic EPS: -1.70
NURS.V cash_flow (annual, 2022-12-31) — Beginning Cash Position: 6381.00
NURS.V cash_flow (annual, 2022-12-31) — Capital Expenditure: -66519.00
NURS.V balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 18663.00
NURS.V balance_sheet (annual, 2022-12-31) — Capital Stock: 6233518.00
NURS.V balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 2432421.00
NURS.V balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 2432421.00
NURS.V balance_sheet (annual, 2022-12-31) — Cash Financial: 2432421.00
NURS.V cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 2816306.00
NURS.V cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -66519.00
NURS.V cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: -329602.00
NURS.V cash_flow (annual, 2022-12-31) — Change In Account Payable: 252142.00
NURS.V cash_flow (annual, 2022-12-31) — Change In Income Tax Payable: 0.00
NURS.V cash_flow (annual, 2022-12-31) — Change In Inventory: -262816.00
NURS.V cash_flow (annual, 2022-12-31) — Change In Other Working Capital: 1343717.00
NURS.V cash_flow (annual, 2022-12-31) — Change In Payable: 252142.00
NURS.V cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: 252142.00
NURS.V cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: -32638.00
NURS.V cash_flow (annual, 2022-12-31) — Change In Receivables: -5056.00
NURS.V cash_flow (annual, 2022-12-31) — Change In Tax Payable: 0.00
NURS.V cash_flow (annual, 2022-12-31) — Change In Working Capital: 1295349.00
NURS.V cash_flow (annual, 2022-12-31) — Changes In Account Receivables: -5056.00
NURS.V cash_flow (annual, 2022-12-31) — Changes In Cash: 2420185.00
NURS.V balance_sheet (annual, 2022-12-31) — Common Stock: 6233518.00
NURS.V balance_sheet (annual, 2022-12-31) — Common Stock Equity: -356841.00
NURS.V cash_flow (annual, 2022-12-31) — Common Stock Issuance: 2430860.00
NURS.V income_statement (annual, 2022-12-31) — Cost Of Revenue: 2432929.00
NURS.V balance_sheet (annual, 2022-12-31) — Current Assets: 2618138.00
NURS.V balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 18663.00
NURS.V balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 18663.00
NURS.V balance_sheet (annual, 2022-12-31) — Current Deferred Liabilities: 1703821.00
NURS.V balance_sheet (annual, 2022-12-31) — Current Deferred Revenue: 1703821.00
NURS.V balance_sheet (annual, 2022-12-31) — Current Liabilities: 3231229.00
NURS.V cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 37283.00
NURS.V income_statement (annual, 2022-12-31) — Depreciation Amortization Depletion Income Statement: 37283.00
NURS.V cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 37283.00
NURS.V income_statement (annual, 2022-12-31) — Depreciation And Amortization In Income Statement: 37283.00
NURS.V income_statement (annual, 2022-12-31) — Diluted Average Shares: 3526305.00
NURS.V income_statement (annual, 2022-12-31) — Diluted EPS: -1.70
NURS.V income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -5995220.00
NURS.V balance_sheet (annual, 2022-12-31) — Duefrom Related Parties Current: 0.00
NURS.V balance_sheet (annual, 2022-12-31) — Duefrom Related Parties Non Current: 0.00
NURS.V balance_sheet (annual, 2022-12-31) — Dueto Related Parties Current: 761253.00
NURS.V income_statement (annual, 2022-12-31) — EBIT: -5992954.00
NURS.V income_statement (annual, 2022-12-31) — EBITDA: -5955671.00
NURS.V cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: 5855.00
NURS.V cash_flow (annual, 2022-12-31) — End Cash Position: 2432421.00
NURS.V cash_flow (annual, 2022-12-31) — Financing Cash Flow: 2816306.00
NURS.V cash_flow (annual, 2022-12-31) — Free Cash Flow: -396121.00
NURS.V income_statement (annual, 2022-12-31) — Gain On Sale Of Security: 4331.00
NURS.V balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: -109069.00
NURS.V income_statement (annual, 2022-12-31) — General And Administrative Expense: 2853342.00
NURS.V balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 255592.00
NURS.V balance_sheet (annual, 2022-12-31) — Gross PPE: 38615.00
NURS.V income_statement (annual, 2022-12-31) — Gross Profit: 1835502.00
NURS.V income_statement (annual, 2022-12-31) — Insurance And Claims: 22841.00
NURS.V income_statement (annual, 2022-12-31) — Interest Expense: 2266.00
NURS.V income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 2266.00
NURS.V income_statement (annual, 2022-12-31) — Interest Income: 0.00
NURS.V income_statement (annual, 2022-12-31) — Interest Income Non Operating: 0.00
NURS.V balance_sheet (annual, 2022-12-31) — Inventory: 104271.00
NURS.V balance_sheet (annual, 2022-12-31) — Invested Capital: -356841.00
NURS.V cash_flow (annual, 2022-12-31) — Investing Cash Flow: -66519.00
NURS.V cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 2430860.00
NURS.V balance_sheet (annual, 2022-12-31) — Leases: 38615.00
NURS.V cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -22217.00
NURS.V cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 2430860.00
NURS.V income_statement (annual, 2022-12-31) — Net Income: -5995220.00
NURS.V income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -5995220.00
NURS.V income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -5995220.00
NURS.V income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -5995220.00
NURS.V income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -5995220.00
NURS.V cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -5995220.00
NURS.V income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -5995220.00
NURS.V cash_flow (annual, 2022-12-31) — Net Intangibles Purchase And Sale: -66519.00
NURS.V income_statement (annual, 2022-12-31) — Net Interest Income: -101507.00
NURS.V cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -22217.00
NURS.V cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -22217.00
NURS.V income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -101507.00
NURS.V cash_flow (annual, 2022-12-31) — Net Other Financing Charges: 407663.00
NURS.V balance_sheet (annual, 2022-12-31) — Net PPE: 18703.00
NURS.V cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: 0.00
NURS.V balance_sheet (annual, 2022-12-31) — Net Tangible Assets: -612433.00
NURS.V balance_sheet (annual, 2022-12-31) — Non Current Deferred Liabilities: 18045.00
NURS.V balance_sheet (annual, 2022-12-31) — Non Current Deferred Revenue: 18045.00
NURS.V balance_sheet (annual, 2022-12-31) — Non Current Prepaid Assets: 0.00
NURS.V income_statement (annual, 2022-12-31) — Normalized EBITDA: -2021361.00
NURS.V income_statement (annual, 2022-12-31) — Normalized Income: -2060910.00
NURS.V cash_flow (annual, 2022-12-31) — Operating Cash Flow: -329602.00
NURS.V income_statement (annual, 2022-12-31) — Operating Income: -1959403.00
NURS.V income_statement (annual, 2022-12-31) — Operating Revenue: 4268431.00
NURS.V balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 37842815.00
NURS.V balance_sheet (annual, 2022-12-31) — Other Equity Adjustments: -109069.00
NURS.V balance_sheet (annual, 2022-12-31) — Other Equity Interest: 306826.00
NURS.V income_statement (annual, 2022-12-31) — Other Gand A: 1185296.00
NURS.V income_statement (annual, 2022-12-31) — Other Income Expense: -3934310.00
NURS.V cash_flow (annual, 2022-12-31) — Other Non Cash Items: 3863717.00
NURS.V income_statement (annual, 2022-12-31) — Other Operating Expenses: 649504.00
NURS.V balance_sheet (annual, 2022-12-31) — Other Properties: 38615.00
NURS.V balance_sheet (annual, 2022-12-31) — Other Receivables: 5056.00
NURS.V income_statement (annual, 2022-12-31) — Other Taxes: 0.00
NURS.V balance_sheet (annual, 2022-12-31) — Payables: 1508745.00
NURS.V balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 1508745.00
NURS.V balance_sheet (annual, 2022-12-31) — Prepaid Assets: 62395.00
NURS.V income_statement (annual, 2022-12-31) — Pretax Income: -5995220.00
NURS.V balance_sheet (annual, 2022-12-31) — Properties: 0.00
NURS.V cash_flow (annual, 2022-12-31) — Purchase Of Intangibles: -66519.00
NURS.V cash_flow (annual, 2022-12-31) — Purchase Of PPE: 0.00
NURS.V balance_sheet (annual, 2022-12-31) — Receivables: 19051.00
NURS.V income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 2432929.00
NURS.V income_statement (annual, 2022-12-31) — Reconciled Depreciation: 37283.00
NURS.V income_statement (annual, 2022-12-31) — Rent And Landing Fees: 51131.00
NURS.V income_statement (annual, 2022-12-31) — Rent Expense Supplemental: 51131.00
NURS.V cash_flow (annual, 2022-12-31) — Repayment Of Debt: -22217.00
NURS.V income_statement (annual, 2022-12-31) — Restructuring And Mergern Acquisition: 3938641.00
NURS.V balance_sheet (annual, 2022-12-31) — Retained Earnings: -6788116.00
NURS.V income_statement (annual, 2022-12-31) — Salaries And Wages: 1594074.00
NURS.V income_statement (annual, 2022-12-31) — Selling And Marketing Expense: 254776.00
NURS.V income_statement (annual, 2022-12-31) — Selling General And Administration: 3108118.00
NURS.V balance_sheet (annual, 2022-12-31) — Share Issued: 37842815.00
NURS.V income_statement (annual, 2022-12-31) — Special Income Charges: -3938641.00
NURS.V cash_flow (annual, 2022-12-31) — Stock Based Compensation: 300000.00
NURS.V balance_sheet (annual, 2022-12-31) — Stockholders Equity: -356841.00
NURS.V balance_sheet (annual, 2022-12-31) — Tangible Book Value: -612433.00
NURS.V income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
NURS.V income_statement (annual, 2022-12-31) — Tax Provision: 0.00
NURS.V income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.00
NURS.V balance_sheet (annual, 2022-12-31) — Taxes Receivable: 13995.00
NURS.V balance_sheet (annual, 2022-12-31) — Total Assets: 2892433.00
NURS.V balance_sheet (annual, 2022-12-31) — Total Capitalization: -356841.00
NURS.V balance_sheet (annual, 2022-12-31) — Total Debt: 18663.00
NURS.V balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: -356841.00
NURS.V income_statement (annual, 2022-12-31) — Total Expenses: 6227834.00
NURS.V balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 3249274.00
NURS.V balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 274295.00
NURS.V balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 18045.00
NURS.V income_statement (annual, 2022-12-31) — Total Other Finance Cost: 99241.00
NURS.V income_statement (annual, 2022-12-31) — Total Unusual Items: -3934310.00
NURS.V income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: -3934310.00
NURS.V balance_sheet (annual, 2022-12-31) — Working Capital: -613091.00
NURS.V income_statement (annual, 2023-12-31) — +Operating Expense: 6426584.00
NURS.V income_statement (annual, 2023-12-31) — +Total Revenue: 11509496.00
NURS.V balance_sheet (annual, 2023-12-31) — Accounts Payable: 833724.00
NURS.V balance_sheet (annual, 2023-12-31) — Accounts Receivable: 23799.00
NURS.V balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -38615.00
NURS.V cash_flow (annual, 2023-12-31) — Asset Impairment Charge: 0.00
NURS.V income_statement (annual, 2023-12-31) — Basic Average Shares: 38059384.00
NURS.V income_statement (annual, 2023-12-31) — Basic EPS: -0.05
NURS.V cash_flow (annual, 2023-12-31) — Beginning Cash Position: 2432421.00
NURS.V cash_flow (annual, 2023-12-31) — Capital Expenditure: -211496.00
NURS.V balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 0.00
NURS.V balance_sheet (annual, 2023-12-31) — Capital Stock: 6533518.00
NURS.V balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 1783787.00
NURS.V balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 1783787.00
NURS.V balance_sheet (annual, 2023-12-31) — Cash Financial: 1783787.00
NURS.V cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: 31212.00
NURS.V cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: -302225.00
NURS.V cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: -402177.00
NURS.V cash_flow (annual, 2023-12-31) — Change In Account Payable: 1134369.00
NURS.V cash_flow (annual, 2023-12-31) — Change In Income Tax Payable: 13995.00
NURS.V cash_flow (annual, 2023-12-31) — Change In Inventory: 518.00
NURS.V cash_flow (annual, 2023-12-31) — Change In Other Working Capital: -2558.00
NURS.V cash_flow (annual, 2023-12-31) — Change In Payable: 1148364.00
NURS.V cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 1148364.00
NURS.V cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: -146110.00
NURS.V cash_flow (annual, 2023-12-31) — Change In Receivables: -18743.00
NURS.V cash_flow (annual, 2023-12-31) — Change In Tax Payable: 13995.00
NURS.V cash_flow (annual, 2023-12-31) — Change In Working Capital: 981471.00
NURS.V cash_flow (annual, 2023-12-31) — Changes In Account Receivables: -18743.00
NURS.V cash_flow (annual, 2023-12-31) — Changes In Cash: -673190.00
NURS.V balance_sheet (annual, 2023-12-31) — Common Stock: 6533518.00
NURS.V balance_sheet (annual, 2023-12-31) — Common Stock Equity: -1830917.00
NURS.V cash_flow (annual, 2023-12-31) — Common Stock Issuance: 0.00
NURS.V cash_flow (annual, 2023-12-31) — Common Stock Payments: 0.00
NURS.V income_statement (annual, 2023-12-31) — Cost Of Revenue: 6548046.00
NURS.V balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 121017.00
NURS.V balance_sheet (annual, 2023-12-31) — Current Assets: 2064487.00
NURS.V balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 0.00
NURS.V balance_sheet (annual, 2023-12-31) — Current Deferred Liabilities: 1691832.00
NURS.V balance_sheet (annual, 2023-12-31) — Current Deferred Revenue: 1691832.00
NURS.V balance_sheet (annual, 2023-12-31) — Current Liabilities: 4407450.00
NURS.V cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 108389.00
NURS.V income_statement (annual, 2023-12-31) — Depreciation Amortization Depletion Income Statement: 108389.00
NURS.V cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 108389.00
NURS.V income_statement (annual, 2023-12-31) — Depreciation And Amortization In Income Statement: 108389.00
NURS.V income_statement (annual, 2023-12-31) — Diluted Average Shares: 38059384.00
NURS.V income_statement (annual, 2023-12-31) — Diluted EPS: -0.05
NURS.V income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -1937351.00
NURS.V balance_sheet (annual, 2023-12-31) — Duefrom Related Parties Current: 31746.00
NURS.V balance_sheet (annual, 2023-12-31) — Duefrom Related Parties Non Current: 58869.00